What is BPC-157?
BPC-157 is a chain of 15 amino acids based on a protective protein found in stomach juice. Researchers have studied it mostly in animals, where it's been examined for tendon, muscle, and gut-lining repair — and that preclinical caveat matters, so our articles say it plainly.
Here you'll find how BPC-157 is thought to work, what the evidence covers, dosing questions, and comparisons with TB-500. It's available only by prescription after a licensed provider reviews your request.
63 articles on this topic
-
1984 Nobel Prize in Chemistry: Making Peptides
Bruce Merrifield’s bead method made peptides easier to build. The breakthrough explains modern synthesis—and why purity testing still matters.
-
FDA Peptide Policy: Under Review, Not in Effect Yet
The White House logged a new FDA peptide policy notice on October 14, 2026, but the text is not public yet. Here is what the official record confirms, what unnamed sources reported about BPC-157, and what stays the same today.
-
BPC-157 for Ligaments: Animal Evidence, Human Gaps
The ligament claim comes from a rat knee study. Human trials have not shown that BPC-157 repairs an ACL tear or shortens recovery from a sprain.
-
What Is Bacteriostatic Water? Meaning and Safety
Bacteriostatic water contains a preservative that limits bacterial growth. The medication’s instructions decide whether it is the right mixing liquid.
-
10 Questions to Ask Before BPC-157
Ten questions explain what a BPC-157 visit needs to cover, from medical history and evidence limits to sport testing and follow-up.
-
TB-500 Myths: Ten Claims Checked Against Studies
TB-500's benefits in humans have not been established. Ten common claims get graded against the actual molecule, study and outcome behind them.
-
What Is a Bulk Drug Substance? API, Explained
A bulk drug substance is the active ingredient before it becomes a finished medicine. Its exact chemical form, source and batch testing matter.
-
Phases of Clinical Trials: What 1, 2, 3 and 4 Mean
Phase 1 checks early safety. Phases 2 and 3 test treatment effects, and phase 4 studies medicines after they reach the market.
-
TB-500 News Update: October 2026
A new rat study adds tendon data, while the human evidence gap remains. July's FDA review and September's sports list answer different questions.
-
Peptide Myths: 10 Common Claims Checked
Ten things people say about peptides online, from "they're steroids" to "drug tests can't find them," graded against the studies and the rules that can actually answer them.
-
Should I Take BPC-157? How a Provider Decides
Should I take BPC-157? It may be worth discussing for a specific, examined problem, but a provider first checks the injury, the gut, drug testing, cancer history, pregnancy and your other medicines.
-
What Is Off-Label Use? Meaning, Legality, Examples
Off-label use means prescribing an approved drug in a way its label doesn't describe. It's legal and common, and it isn't the same thing as a compounded or an unapproved drug.
-
12 Questions to Ask About Peptide Therapy
Twelve questions worth bringing to a peptide visit, grouped by what they uncover: the evidence, the review status, your own health and the vial itself, with why each is asked and what a straight answer sounds like.
-
Wolverine Peptide Study: Use Is Up, Proof Isn't
A September preprint read de-identified doctors' notes and found new BPC-157 users up 33-fold since 2020, increasingly male and younger. It shows who is using it and where they get it, not whether it works.
-
What Is Bioavailability? A Plain-English Guide
Bioavailability tells you how much of a medication reaches the place where the body can use it, and how quickly it gets there. The route and the exact formulation both matter.
-
KPV FDA Review: What the July Vote Really Changed
KPV has never been approved as a U.S. drug. A July 2026 advisory vote favored possible 503A listing, but it did not change the list or approve a product.
-
WADA Prohibited List 2027: GLP-1s Off, BPC-157 On
WADA published its 2027 list on September 21. The weight-loss drugs stay on a watch list rather than the prohibited list, the peptides stay where they were, and a prescription is still not an exemption.
-
BPC-157 News Update: September 2026
A July FDA advisory vote moved the conversation forward, but it did not change the law or establish that BPC-157 works in people. A new rat study adds evidence, with the same important limit: it was not a human trial.
-
Hims Peptides: What Hims & Hers Plans to Sell
Hims & Hers says a peptide and wellness category is coming, but the rollout is phased. Some offerings are planned for 2026, while BPC-157 depends on unfinished FDA rulemaking.
-
What Is an IND? A Plain-English FDA Guide
An IND is the filing that lets a sponsor begin testing an investigational drug in people. It opens a research path, not a sales or prescription path.
Page 1 of 4 · 63 articles